DEXCOM LIFTS 2026 REVENUE GUIDANCE, ADDS $1B BUYBACK

Dexcom raised its full-year 2026 revenue guidance to $5.20-$5.25 billion, implying 12-13% growth, after third-quarter sales rose 11% to $1.344 billion from $1.209 billion a year earlier. The growth split sharply by geography: U.S. revenue climbed 14% while international sales rose just 5% on a reported basis. The company also authorized a new $1 billion share buyback alongside the results. $DXCM is leaning hard on its home market to carry the growth story.